Some 200 Israelis have contracted the JN.1 coronavirus variant, a highly contagious sub-variant starting to dominate the latest wave of COVID-19 infections, Maariv reported on Monday.
The Health Ministry in Israel has confirmed a small rise in morbidity rates, with around 200 cases of a COVID-19 sub-variant recorded in the country. This information aligns with concerns expressed by the Centers for Disease Control and Prevention (CDC) in the United States. The CDC had issued a warning, stating that the rapid spread of the sub-variant could necessitate U.S. hospitals to start preparing for a potential surge in hospitalizations. Monitoring and responding to emerging variants continue to be a global priority in managing the ongoing COVID-19 pandemic.
The information provided indicates that early data suggests reduced effectiveness of existing vaccines in neutralizing the JN.1 variant. The Centers for Disease Control and Prevention (CDC) anticipates that this variant will continue to spread. However, the extent to which JN.1 may contribute to increases in COVID-19 cases and its impact during the rest of December is not fully known at this time. Ongoing monitoring, research, and public health measures will be crucial in understanding and responding to the evolving situation. Israelis have contracted
It’s positive to note that a group of experts assembled by the World Health Organization (WHO) has concluded that the changes observed in the JN.1 variant are not significant enough to necessitate a new revision of the current COVID-19 vaccines. Continuous monitoring and evaluation of emerging variants are essential, and the consensus among experts will guide decisions on vaccine effectiveness and potential updates. Public health organizations worldwide will continue to assess and respond to new information to ensure the ongoing efficacy of vaccination efforts.